TrialInternational journal of radiation oncology, biology, physics2023

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.

Casey L Liveringhouse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.